ARS PHARMACEUTICALS INC (SPRY)
US82835W1080 - Common Stock
Taking everything into account, SPRY scores 4 out of 10 in our fundamental rating. SPRY was compared to 572 industry peers in the Biotechnology industry. SPRY has a great financial health rating, but its profitability evaluates not so good. SPRY is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SPRY had negative earnings in the past year.
SPRY had a negative operating cash flow in the past year.
SPRY had negative earnings in each of the past 5 years.
SPRY had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SPRY has a Return On Assets of -22.57%. This is in the better half of the industry: SPRY outperforms 73.98% of its industry peers.
SPRY has a Return On Equity of -24.43%. This is amongst the best in the industry. SPRY outperforms 82.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.57% | ||
| ROE | -24.43% | ||
| ROIC | N/A |
ROA(3y)-20.82%
ROA(5y)-44.89%
ROE(3y)-21.59%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SPRY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SPRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SPRY has more shares outstanding
The number of shares outstanding for SPRY has been increased compared to 5 years ago.
There is no outstanding debt for SPRY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 38.89 indicates that SPRY is not in any danger for bankruptcy at the moment.
The Altman-Z score of SPRY (38.89) is better than 97.52% of its industry peers.
SPRY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 38.89 |
ROIC/WACCN/A
WACC10.88%
2.3 Liquidity
A Current Ratio of 12.56 indicates that SPRY has no problem at all paying its short term obligations.
With an excellent Current ratio value of 12.56, SPRY belongs to the best of the industry, outperforming 85.31% of the companies in the same industry.
SPRY has a Quick Ratio of 12.52. This indicates that SPRY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 12.52, SPRY belongs to the top of the industry, outperforming 85.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.56 | ||
| Quick Ratio | 12.52 |
3. Growth
3.1 Past
The earnings per share for SPRY have decreased strongly by -288.89% in the last year.
Looking at the last year, SPRY shows a very strong growth in Revenue. The Revenue has grown by 90.22%.
EPS 1Y (TTM)-288.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)90.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, SPRY will show a very strong growth in Earnings Per Share. The EPS will grow by 32.33% on average per year.
Based on estimates for the next years, SPRY will show a very strong growth in Revenue. The Revenue will grow by 764.32% on average per year.
EPS Next Y-4.24%
EPS Next 2Y16.05%
EPS Next 3Y28.66%
EPS Next 5Y32.33%
Revenue Next Year196518%
Revenue Next 2Y10839.2%
Revenue Next 3Y2696.28%
Revenue Next 5Y764.32%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
SPRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SPRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SPRY's earnings are expected to grow with 28.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.05%
EPS Next 3Y28.66%
5. Dividend
5.1 Amount
SPRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARS PHARMACEUTICALS INC
NASDAQ:SPRY (1/14/2025, 8:06:31 PM)
Premarket: 11.4801 +0.12 (+1.06%)11.36
+0.1 (+0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.79%
Inst Owner ChangeN/A
Ins Owners18.18%
Ins Owner Change-0.76%
Market Cap1.10B
Analysts88
Price Target29.58 (160.39%)
Short Float %20.65%
Short Ratio10.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.09%
Min EPS beat(2)-32.93%
Max EPS beat(2)-9.24%
EPS beat(4)2
Avg EPS beat(4)2.69%
Min EPS beat(4)-32.93%
Max EPS beat(4)50.98%
EPS beat(8)5
Avg EPS beat(8)88.8%
EPS beat(12)6
Avg EPS beat(12)53.26%
EPS beat(16)7
Avg EPS beat(16)24.54%
Revenue beat(2)1
Avg Revenue beat(2)100.81%
Min Revenue beat(2)-50.98%
Max Revenue beat(2)252.6%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)70.65%
EPS NY rev (1m)-18.27%
EPS NY rev (3m)12.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)487.01%
Revenue NY rev (1m)-30.09%
Revenue NY rev (3m)367.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 429.94 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.49 | ||
| P/tB | 5.71 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.03
BVpS2.07
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.57% | ||
| ROE | -24.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-20.82%
ROA(5y)-44.89%
ROE(3y)-21.59%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 263.49% | ||
| Cap/Sales | 6.46% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 12.56 | ||
| Quick Ratio | 12.52 | ||
| Altman-Z | 38.89 |
F-Score3
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)159.29%
Cap/Depr(5y)128.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-288.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-4.24%
EPS Next 2Y16.05%
EPS Next 3Y28.66%
EPS Next 5Y32.33%
Revenue 1Y (TTM)90.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year196518%
Revenue Next 2Y10839.2%
Revenue Next 3Y2696.28%
Revenue Next 5Y764.32%
EBIT growth 1Y-92.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.18%
EBIT Next 3Y51.13%
EBIT Next 5YN/A
FCF growth 1Y37.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.99%
OCF growth 3YN/A
OCF growth 5YN/A